

Confirmed Speakers

Evotec Prize for Excellence in Molecular Design

PL10 - Modulation of Protein – Protein Interactions by Means of Peptidomimetics



Prof. Steven BALLEET
(VRIJE UNIVERSITEIT BRUSSEL, Brussels, Belgium)

Galapagos Award For Drug Discovery Chemistry

PL20 - Peptide, A Manifesto



Prof. Philippe KAROYAN
(SORBONNE UNIVERSITÉ, VILLEBON SUR YVETTE, France)

Confirmed Plenary Speakers

PL19 - Expansion of the Druggable Genome through Rational Approaches to Molecular Glue Discovery



Dr Rohan BECKWITH
(NEOMORPH INC., San Diego, United States)

PL16 - Discovery of the Clinical Candidate ACT-777991, a Potent CXCR3 Antagonist with Therapeutic Potential in Autoimmune Diseases



Dr Eva CAROFF
(IDORSIA PHARMACEUTICALS LTD, Allschwil, Switzerland)

PL04 - Electrochemistry in High-Throughput



Dr Nessa CARSON
(ASTRAZENECA, Macclesfield, United Kingdom)

PL12 - Development of SARS Coronavirus 3CL Protease Inhibitors with an Electrophilic aryl-ketone Warhead



Prof. Yoshio HAYASHI
(TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES, Tokyo, Japan)

PL03 - Discovery of Novel Microbiome-Sparing Antibiotics with Activity Against Gram-Negative Pathogens



Prof. Paul J. HERGENROTHER
(UNIVERSITY OF ILLINOIS, Urbana, United States)

PL18 - A Tricycle Journey to in vivo Degradable of the Oncogenic Transcription Factor BCL6

Confirmed Speakers



Prof. Swen HOELDER
(THE INSTITUTE OF CANCER RESEARCH, Sutton, United Kingdom)

PL02 - Identification of CDK8 Inhibitors as Inducers of Tendon Cell Differentiation through Phenotypic Screening and Chemoproteomics



Dr Jean-Baptiste LANGLOIS
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)

PL08 - Leucettinib-21, A DYRK1A Inhibitor Drug Candidate Aiming at the Correction of Cognitive Disorders in People with Down Syndrome or Alzheimer's Disease



Dr Laurent MEIJER
(PERHA PHARMACEUTICALS, Roscoff, France)

PL05 - Stabilizing Relevant GPCR Conformations to Discover Therapeutic Antibodies



Dr Christel MENET
(CONFO THERAPEUTICS, Brussels, Belgium)

PL14 - BacPROTACs Mediate Targeted Protein Degradation in Bacteria



Prof. Francesca Ester MORREALE
(THE FRANCIS CRICK INSTITUTE, London, United Kingdom)

PL11 - Structural Biology Supporting Medicinal Chemistry of Purine Receptors



Prof. Christa MÜLLER
(UNIVERSITY OF BONN, Bonn, Germany)

PL13 - Inhibitors of the Mitochondrial Sirtuins 3 and 5



Prof. Christian A. OLSEN
(UNIVERSITY OF COPENHAGEN, Copenhagen, Denmark)

PL07 - Discovery of GLPG3970, A First-in-class SIK2/SIK3 Inhibitor Evaluated in Clinical Trials for the Treatment of Autoimmune and Inflammatory Diseases



Dr Christophe PEIXOTO
(GALAPAGOS, Romainville, France)

PL01 - Fragment-based Design of Methionine Adenosyl Transferase (MAT2a) Inhibitors with Anti-tumour Effect

Confirmed Speakers



Dr Marianne SCHIMPL
(ASTRAZENECA, Cambridge, United Kingdom)

PL15 - Metallo-Enzymes - From Functions to Drugs



Prof. Christopher J. SCHOFIELD
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

PL17 - Bifunctional Molecules for Exploring and Treating Human Disease



Prof. David SPIEGEL
(YALE UNIVERSITY, New Haven, United States)

PL06 - LipMete (Lipophilic Metabolism Efficiency) as a Simple Guide for Half-Life and Dosing Regimen Prediction of Oral Drugs



Dr Antonia F. STEPAN
(F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland)

PL09 - Discovery of Linvencorvir (RG7907), a Hepatitis B Virus Core Protein Allosteric Modulator, for the Treatment of Chronic HBV Infection



Dr Wei ZHU
(CHINA INNOVATION CENTER OF ROCHE (CICOR), Shanghai, China)

Confirmed Oral Communications

OC07 - Discovery of an Oral, Rule-of-5 Compliant, IL-17A Protein-Protein Interaction Modulator (IL-17A PPI) for the Treatment of Psoriasis and other Inflammatory Diseases.



Dr Mark D. ANDREWS
(LEO PHARMA, Ballerup, Denmark)

OC05 - Tackling LysS, a New Target for Tuberculosis



Dr Laura A.T. CLEGHORN
(UNIVERSITY OF DUNDEE, Dundee, United Kingdom)

OC08 - Small-Molecule Inhibitor Targeting PD-1/PD-L1 Interaction Restores T-Cell Function



Prof. Helena FLORINDO
(IMED - UNIVERSITY OF LISBON, Lisbon, Portugal)

OC06 - Historical Evolution and Lessons Learned from an RSV Non Nucleosides Polymerase Inhibitor Program

Confirmed Speakers



Dr Sandrine GROSSE
(JANSSEN, Beerse, Belgium)

OC03 - Scaffold out of the Blue: Azulenes for Medicinal Chemistry



Dr Jörg KLEY
(BOEHRINGER INGELHEIM, Biberach an der Riss, Germany)

OC01 - Experiences from CETSA Screens for Hit Discovery versus Challenging Targets



Dr Alice LANNE
(ASTRAZENECA, Macclesfield, United Kingdom)

OC02 - Potential of Chloroalkene as Amide Bond Isostere



Prof. Tetsuo NARUMI
(SHIZUOKA UNIVERSITY, Hamamatsu, Japan)

OC04 - Unravelling the Potential of the Type 2 Lysophosphatidic Acid Receptor (LPA2) for Central Nervous System Pathologies



Prof. Silvia ORTEGA GUTIERREZ
(COMPLUTENSE UNIVERSITY OF MADRID, Madrid, Spain)